Clinical Trials Browser

Phase 1 × Microsatellite Instability × 30 days × Clear all

NCT06625515 2026-02-24

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Phase 1 Terminated

GastrointestinalGynecologic

Colonic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms, Microsatellite Instability